Advertisement

Measurement of Complement Activation

  • Tom Eirik Mollnes
Part of the Methods in Molecular Biology book series (MIMB, volume 225)

Abstract

Complement is a humoral defense system that protects the host from microorganisms by inducing an inflammatory reaction at the site of invasion. However, complement activation is not limited to microbial protection, but is generally activated in any tissue damage irrespective of the stimulus that initiated the reaction. Thus, complement is a double-edged sword which, when activated improperly, may contribute to inflammation and tissue damage. Weisman et al. demonstrated in 1990 that specific complement inhibition markedly reduced tissue damage in experimental myocardial infarction (1), a number of animal and clinical studies have documented that activation of complement contributes to the ischemia/reperfusion injury in general, and to the pathophysiology of various autoimmune diseases, trauma, systemic inflammatory response syndrome, septicemia, and transplant rejection (for review, see refs. 2, 3, 4, 5).

Keywords

Activation Product Systemic Inflammatory Response Syndrome Complement Activation Capture Antibody Experimental Myocardial Infarction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Weisman, H. F., Bartow, T., Leppo, M. K., Marsh, H. C., Jr., Carson, G. R., Concino, M. F., et al. (1990) Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249, 146–151.PubMedCrossRefGoogle Scholar
  2. 2.
    Asghar, S. S. and Pasch, M. C. (2000) Therapeutic inhibition of the complement system. Front Biosci. 5, E63–E82.PubMedCrossRefGoogle Scholar
  3. 3.
    Sahu, A. and Lambris, J. D. (2000) Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology 49, 133–148.PubMedCrossRefGoogle Scholar
  4. 4.
    Makrides, S. C. (1998) Therapeutic inhibition of the complement system. Pharmacol. Rev. 50, 59–87.PubMedGoogle Scholar
  5. 5.
    Kirschfink, M. (1997) Controlling the complement system in inflammation. Immunopharmacology 38, 51–62.PubMedCrossRefGoogle Scholar
  6. 6.
    Mollnes, T. E. and Harboe, M. (1993) Neoepitope expression during complement activation — a model for detecting antigenic changes in proteins and activation of cascades. Immunologist 1, 43–49.Google Scholar
  7. 7.
    Mollnes, T. E., Lea, T., Harboe, M., and Tschopp, J. (1985) Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma. Scand. J. Immunol. 22, 183–195.PubMedCrossRefGoogle Scholar
  8. 8.
    Link, C., Hawlisch, H., Vilsendorf, A. M. Z., Gyleruz, S., Nagel, E., and Köhl, J. (1999) Selection of phage-displayed anti-guinea pig C5 or C5a antibodies and their application in xenotransplantation. Mol. Immunol. 36, 1235–1247.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2003

Authors and Affiliations

  • Tom Eirik Mollnes
    • 1
  1. 1.University of OsloOsloNorway

Personalised recommendations